- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04256200
Efficacy of Dienogest Versus Oral Contraceptive Pills on Pain Associated With Endometriosis
April 14, 2021 updated by: Antoine Abou Moussa, American University of Beirut Medical Center
Endometriosis is a chronic inflammatory disease, frequently associated with dysmenorrhea, dyspareunia and abdomino-pelvic pain limiting quality of life.
Most medical therapies aim to alleviate the severity of symptoms.
Recent guidelines recommend the use of either OCPs or progestins as a first-line treatment of pain associated with endometriosis.
The effectiveness of both OCPs and dienogest, a fourth-generation progestin, for endometriosis treatment has been demonstrated.
The literature is rich with data comparing the use of Visanne or OCPs to placebo or GnRH analogs.
However, there are no head to head studies comparing their efficacy in the management of endometriosis associated pain.
The study aims to evaluate if Dienogest (Visanne) is not inferior in efficacy to oral contraceptive pills (Yasmin) in controlling pain associated with endometriosis?
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Endometriosis is defined as the presence of endometrial tissue outside the uterus, which induces a chronic inflammatory reaction.
It is an estrogen-dependent associated with pelvic pain and infertility.
It is a relatively common chronic gynecological disease that affects approximately 10% of reproductive aged women.
Patients with endometriosis often suffer from dysmenorrhea, dyspareunia, dysuria, and chronic abdominal or pelvic pain, resulting in a severely limited quality of life.
The aim of most medical therapies is to alleviate the severity of symptoms.
Commonly used hormonal therapies include combined oral contraceptives (OCP), progestogens, gonadotropin-releasing hormone (GnRH) agonists, androgens and antiprogestogens, all of which are considered to have similar efficacy but different tolerability profiles, which are often suboptimal.
To date, the most widely used agent for the medical treatment of endometriosis is oral contraceptive (albeit off-label).
In particular, evidence supporting the efficacy of estrogen-progestin therapy (EP) in pain control and reducing the risk of recurrence in women undergoing surgery for endometriosis.
In recent years, the effectiveness of dienogest, a fourth-generation progestin, for endometriosis treatment has been demonstrated.
Dienogest seems to be as effective as gonadotrophin-releasing hormone-a (GnRH-a) in terms of endometriosis-related pelvic pain improvement.
The aim of this study is to evaluate the efficacy of Visanne versus OCP treatment of endometriosis associated pelvic pain in a double-blinded randomized controlled pilot study.
It is a two armed pilot study; each group will include 50 patients.
Women with endometriosis will be randomized to receive either DNG (n=50) or OCPs (n=50).
The diagnosis of endometriosis will be by clinical evaluation, laparotomy, laparoscopy, or imaging analysis (combination of magnetic resonance imaging and ultrasonography) of endometriotic ovarian chocolate cysts.The first group will receive Deinogest (Visanne) 2mg/day, orally for 24 weeks.
The second group will receive monophasic combined OCP (Yasmin, Ethinyl Estradiol and Drospirenone) daily for 24 weeks.
The treating physician and the patients will be blinded to the treatment option.
The relief of symptoms and efficacy will be evaluated by questionnaire on follow up visits at 3 and 6 month of the treatment.
Data collected will be analyzed and compared between the 2 groups.
We hypothesize that there will be no difference in pain scores, efficacy and safety between the two treatments.
Study Type
Interventional
Enrollment (Anticipated)
100
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Antoine Abu Musa, M.D.
- Phone Number: 5840 +9611350000
- Email: aa06@aub.edu.lb
Study Locations
-
-
-
Beirut, Lebanon
- Recruiting
- American University of Beirut
-
Contact:
- Antoine Abu Musa, MD
- Phone Number: 4840 +9611350000
- Email: aa06@aub.edu.lb
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 45 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Patients confirmed or suspected of endometriosis on clinical evaluation (VAS score more than 5 and presence of subjective symptoms), surgical or imaging studies, and not taking any pain killer or other hormonal treatment for the moment
- Age 20-45
- Regular menstrual cycles
- The presence of subjective symptoms during menstruation (at least one from among lower abdominal pain, lumbago, defecation pain, nausea, and headache)
- The presence of subjective symptoms during non-menstruation (at least one from among lower abdominal pain, lumbago, defecation pain, dyspareunia, and pain on internal examination).
Exclusion Criteria:
- Undiagnosed genital bleeding
- Use of any hormonal therapy for endometriosis within 16 weeks before enrollment
- A history of severe adverse drug reactions or hypersensitivity to steroid hormone
- Having undergone surgery therapy or surgical examination for endometriosis within a menstrual cycle before the start of medication
- Previous failure of treatment with the OCP used in the current study
- Contraindications to OCP or Dienogest use
- Smokers >35
- A history or complication of thrombosis/embolism
- Migraines with aura
- Depression
- Patients on anti-epileptics
- Diabetes Mellitus with vascular involvement
- Liver diseases
- Known or suspected sex hormone dependent malignancies
- Repeat surgery for endometriosis
- Patient consulting for infertility
- Pregnant or nursing
- Planning for pregnancy in near future.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Dienogest
Deinogest (Visanne) 2mg/day orally for 24 weeks
|
Deinogest (Visanne) 2mg/day, orally for 24 weeks versus combined OCP (Yasmin, 0.03mg
Other Names:
|
Active Comparator: Oral Contraceptive Pills
Oral contraceptive pill (Yasmin, 0.03mg Ethinyl Estradiol and 3mg Drospirenone) orally daily for 24 weeks
|
0.03mg Ethinyl Estradiol and 3mg Drospirenone daily for 24 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Endometriosis-associated pelvic pain
Time Frame: 6 months
|
be the absolute change in endometriosis -associated pelvic pain from baseline to end of treatment, assessed by the Visual Analogue Scale (VAS): with "absence of pain" corresponding to the value "0" and "unbearable pain" corresponding to the value "10"
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Impact on Quality of life
Time Frame: 6 months
|
Outcome quality of life will be assessed using Endometriosis Health Profile 30 (EHP30) with each item of this questionnaire can be answered by choosing one of the following (Never, rarely,sometimes, often and always).
The endometriosis health profile is a patient-generated questionnaire in which the items were developed from interviews with women with the condition ( Obtained from Oxford University Press) .
|
6 months
|
incidence of side effects
Time Frame: 6 months
|
Incidence of possible side effects including headache, migraine,nausea, vomiting, abdominal pain/discomfort, breast pain or tenderness, mood swings, premenstrual syndrome, decreased libido, fatigue, weight changes and menstrual irregularities
|
6 months
|
Patient Tolerability
Time Frame: 6 months
|
Assessing tolerability to side effects via numerical scale from zero to ten ( zero not bothersome at all , ten maximum possible)
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Antoine Abu Musa, MD, American University of Beirut Medical Center
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 7, 2017
Primary Completion (Anticipated)
November 1, 2021
Study Completion (Anticipated)
December 1, 2021
Study Registration Dates
First Submitted
January 15, 2020
First Submitted That Met QC Criteria
February 3, 2020
First Posted (Actual)
February 5, 2020
Study Record Updates
Last Update Posted (Actual)
April 15, 2021
Last Update Submitted That Met QC Criteria
April 14, 2021
Last Verified
April 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Endometriosis
- Physiological Effects of Drugs
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Hormone Antagonists
- Contraceptive Agents, Hormonal
- Reproductive Control Agents
- Contraceptive Agents, Female
- Contraceptives, Oral, Hormonal
- Contraceptive Agents, Male
- Contraceptive Agents
- Contraceptives, Oral
- Contraceptives, Oral, Combined
- Dienogest
Other Study ID Numbers
- OGY.AA.07
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Endometriosis
-
Fabio BarraCompletedEndometriosis | Endometriosis, Rectum | Endometriosis of Vagina | Endometriosis Rectovaginal Septum | Endometriosis Pelvic | Endometriosis of ColonItaly
-
Ospedale Policlinico San MartinoCompletedEndometriosis | Bowel Endometriosis | Endometriosis, Rectum | Endometriosis ColonItaly
-
BioGene Pharmaceutical Ltd.WithdrawnSafety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the Endometriosis (ELTA)Endometriosis | Endometriosis Ovary | Endometriosis, Rectum | Endometriosis ExternaSwitzerland
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...CompletedEndometriosis | Endometriosis-related Pain | Endometriosis Thoracic | Endometriosis of Lung | Endometriosis of PleuraItaly
-
Ospedale Policlinico San MartinoCompletedEndometriosis, Rectum | Endometriosis, SigmoidItaly
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaUnknownBowel Endometriosis | Endometriosis, RectumItaly
-
Ospedale Policlinico San MartinoActive, not recruitingEndometriosis, Rectum | Endometriosis of ColonItaly
-
Catholic University of the Sacred HeartCompletedPelvic Endometriosis | Endometriosis Outside PelvisItaly
-
Semmelweis UniversityUniversity of PecsNot yet recruitingEndometriosis | Endometriosis Ovary | Endometriosis Rectovaginal Septum
-
Catholic University of the Sacred HeartCompletedPelvic Endometriosis | Endometriosis Outside PelvisItaly
Clinical Trials on Dienogest 2 MG Oral Tablet
-
Laboratorios Andromaco S.A.Completed
-
Cara Therapeutics, Inc.CompletedChronic Kidney Diseases | PruritusUnited States
-
Zydus Therapeutics Inc.CompletedPrimary Biliary CirrhosisUnited States
-
Cassava Sciences, Inc.National Institute on Aging (NIA)Completed
-
Fulcrum TherapeuticsCompletedHealthy Adult SubjectsUnited States
-
William TyorNational Institute of Mental Health (NIMH)Recruiting
-
Cara Therapeutics, Inc.RecruitingChronic Kidney Diseases | PruritusUnited States
-
Cara Therapeutics, Inc.RecruitingChronic Kidney Diseases | PruritusUnited States, Korea, Republic of, Australia, Bulgaria, Germany, Hungary, Italy, Poland, Romania, Spain, Argentina, Brazil, Mexico
-
University of MilanNot yet recruiting